H.C. Wainwright resumed coverage on Aethlon Medical with a new price target
$AEMD
Medical/Dental Instruments
Health Care
H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2025 | $1.50 | Neutral | H.C. Wainwright |
| 6/25/2021 | $5.00 → $9.00 | Buy | HC Wainwright & Co. |
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
10-K - AETHLON MEDICAL INC (0000882291) (Filer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50
HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments. Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian
SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P
Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SAN DIEGO, July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification. The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments. Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian
SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P